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Introduction
Of the three genes in the RAS family (KRAS, NRAS and HRAS) , KRAS is the most frequently mutated in human tumors, with an incidence of 70-90% in pancreatic adenocarcinoma, 50% in colon adenocarcinoma, 25-50% in lung adenocarcinoma, and approximately 20% in other types of human cancer, including carcinomas of the lung, colon, and pancreas [1] [2] [3] [4] [5] [6] [7] . RAS oncogene mutations, including KRAS (G12D), are also observed in approximately one third of patients with human malignancies [8, 9] . When mutated at codon 12, 13 or 61, the K-ras mutant proteins remain active and can constitutively transduce signals through the mitogen-activated protein kinase (MAPK) pathway and the phosphoinositide-3-kinase (PI3K) pathway [10] [11] [12] [13] . It has been demonstrated that KRAS mutations represent about 90% of cancer-associated mutations, and that KRAS mutations play an essential role in neoplastic transformation. Cancer-associated RAS mutations, which introduce amino acid substitutions at codons 12, 13, or 61, result in oncogenic Ras proteins that accumulate in the active, GTPbound conformation due to defective guanine nucleotide hydrolysis [9, 14] . Several animal models have been generated to study the role of KRAS mutations in tumorigenesis [1, [15] [16] [17] .
The t(8;21)(q22;q22) translocation is one of the most common structural aberrations observed in acute myelogenous leukemia (AML), and can be found in 5-12% of AML cases and in one third of karyotypically abnormal cases of AML with maturation. The t(8;21)(q22;q22) translocation generates the AML1/ETO oncogenic transcription factor which initiates acute myeloid leukemia by recruiting co-repressor complexes to DNA [18] . This observation alone the propagation of cells harboring the t(8;21) translocation [19] . The full-length AML1-ETO fusion protein, resulting from the t(8;21) (q22;q22) translocation in human acute myeloid that additional mutations are required for leukemogenesis. Several studies have shown that anti-differentiation and pro-proliferative genes cooperate to promote AML in mice [23] [24] [25] . The existence of RAS mutations in diverse myeloid malignancies raises the possibility that they invariably represent secondary events that cooperate with a spectrum of initiating genetic lesions. NRAS (G12D) cooperates with AML1/ETO9a or MLL/ENL to accelerate the onset and reduce overall survival in leukemia [25] . To test our hypothesis that an activating KRAS (G12D) mutation cooperates with AML1-ETO to induce overt AML, we generated a murine transduction and transplantation model with both the KRAS (G12D) mutation and AML1-ETO translocation.
Materials and Methods

Ethics statement
Six-to eight-week-old male C57BL/6J mice were purchased from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). The animal handling and procedures in this study were in accordance with the current Chinese regulation "GB 14925-2010 Laboratory animal requirements of environment and housing facilities" (Chinese version). The complete protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Second Military Medical University. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
Construction of retrovirus vectors
Total RNA was isolated from the peripheral blood mononuclear cells of leukemia patients using ISOGEN-LS (Nippon Gene Co, Tokyo, Japan) according to the manufacturer's protocol. Firststrand complementary DNA (cDNA) was synthesized by reverse transcription using the RNA as the template. The KRAS 5'-TGGGCTAGCATGACTGAGTACAAACTGGTGGTGGTTGGAGCAGATGGTGTTGGGAAAAGCGCACTG-3' (forward); 5'-AAAGCGGCCGCTTACATCACCACACATGGCAATCCC-3' (reverse). The PCR products were analyzed by 1% (w/v) agarose gel electrophoresis (60 min at 100 V in TAE 1× electrophoresis buffer) and visualized using ethidium bromide (BioRad, Hercules, CA, USA) and photographed under UV light. The Nhe I and Not I and cloned separately into the Nhe I and Not I sites of the vector pCDH-CMV-MCS-EF1-copGFP (System Biosciences, Mountain View, CA, USA). The recombinant vectors were named pCDH-K-ras G12D and pCDH-Nras G12D , respectively. The AML1/ETO subcloned into the vector pCDH-CMV-MCS-EF1-copGFP by double digestion with Xba I and Not I. The recombinant vector was named pCDH-AML1/ETO.
Viral production and titer analysis
293T cells were plated into 25 cm 2 tissue culture dishes at a density of 1 x 10 6 with 1 µg of the retroviral vectors (pCDH-K-ras
G12D
, pCDH-N-ras G12D or pCDH-AML1/ETO, respectively) using 2.5 µl FuGENE HD transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. Retroviral supernatant was harvested 48 h after transfection. To assay for viruses carrying × 10 5 polybrene and 2% fetal bovine serum (FBS), and various amounts of test virus were added. On day 3, the virus-containing medium was removed, and the cells were incubated in complete medium. Five days later, transducing units/mL (TU/mL) ± standard deviation.
Cell transplantation pilot study
For the pilot study, six-to eight-week-old male C57BL/6J mice were provided with drinking water containing antibiotics for 1 week, and were then irradiated with X-rays at 8 Gy or 10 Gy (40 per group). Bone marrow cells were harvested from the long bones of male C57BL/6J mice and cultured in IMDM medium (GIBCO, Carlsbad, CA, USA) supplemented with 10% FBS and penicillin/streptomycin (50 U/mL). Cultured untransfected mouse bone marrow cells (0.5-1.0 × 10 6 cells in PBS) were injected into the tail vein of the irradiated mice within 24 h after irradiation. The control group received only normal saline after irradiation (10 per group). The survival time of the mice was observed; 8 Gy led to better survival compared to mice irradiated with 10 Gy (data not shown).
Bone marrow transfection and transplantation model
To transplant transfected bone marrow cells, the bone marrow cells of six-to eight-week-old male C57BL/6J mice were harvested as described as above, randomly divided into four groups (20 mice per group), placed into non-tissue culture-treated 6-well plates (Becton Dickinson) and then coated with 2 NRAS
, at a multiplicity of 40 PFU per cell for 6 h at 37°C. After 6 h, the bone marrow cells were harvested, washed twice with phosphate-buffered saline and used for transplantation. About 1 × 10 6 cells were injected into mice of the relevant groups. The remaining uninfected containing antibiotics for one week; the mice were injected with the cells within 24 h after irradiation. Survival was evaluated 150 days after bone marrow cell transplantation.
Reverse Transcription-PCR (RT-PCR)
Total RNA was isolated from the bone marrow cells of transplanted mice using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) at 8 weeks after transplantation. The concentration of total RNA was (reverse); NRAS (reverse); AML1-ETO (reverse); (reverse).
Flow Cytometric Analysis
Single-cell suspensions were prepared from the spleen, lymph nodes, peripheral blood and central nervous system (CNS) of the mice at a terminal disease stage (severe leukocytosis in peripheral blood smears, moribund appearance). The tissues were minced through a metal mesh, and the bone marrow (BM) anti-mouse Ly-6G (Gr-1, Gr1); APC anti-mouse CD11b (Integrin alpha M, Mac-1 alpha); and APC anti-mouse CD117 (c-Kit, cKit), all of which were obtained from Packard Bioscience Company, Toronto, Ontario, Canada. The cells were stained with the relevant antibodies for 15 min on ice, washed with cold PBS containing Biosciences).
Blood smears and histology
Peripheral blood smears and bone marrow cytospins were stained with Wright-Giemsa stain (Sigma). Tissue specimens for histology were preserved in cold 4% formaldehyde in phosphate-buffered saline (PBS). Embedding, sectioning and staining with hematoxylin and eosin (Sigma) was performed using standard protocols.
Western blot analysis
Cell lysates were prepared by suspending the cells in ice-cold lysis buffer, boiled for 5 min, separated by SDS-PAGE, and transferred to PVDF membranes (Millipore, Billerica, MA, USA), blotted for 1 h with primary antibodies against N-ras (Santa Cruz Biotech), K-ras (Santa Cruz Biotech), AML1-ETO (Santa Cruz Biotech), Pan-ras (Upstate Biotechnologies), MEK and ERK (Santa Cruz Biotech), p-MEK and p-ERK (Cell 
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Tris (pH 7.4), 0.1% Tween-20, and 100 mM NaCl, incubated for 1 h with secondary antibodies conjugated to horseradish peroxidase and washed three times. Blots were developed using the ECL detection system (Pierce, Rockford, IL, USA).
Results
Construction of retroviral vectors
In order to create retroviral vectors to express fusion proteins of K-ras G12D or N-ras G12D , the KRAS G12D and NRAS G12D genes were cloned. The sequences of the resulting PCR products (data not shown) were similar to that reported in GenBank (KRAS, NM_004985 and NRAS, NM_002524). The PCR products were then cloned into the vector pCDH-CMV-MCSsequencing (data not shown). K-ras G12D and N-ras G12D were coexpressed with enhanced vectors expressing KRAS
G12D
, NRAS G12D or AML1-ETO (Fig. 1B) .
The recombinant vectors (pCDH-KRAS
G12D and pCDH-NRAS G12D ), which encode the reporter gene EGFP, were transiently transfected into 293T cells. The transfected cells Fig. 2B ).
We also investigated the composition of the bone marrow cells in the indicated transplanted mice by FACS. The results showed that the bone marrow cells transduced with K-ras G12D + AML1/ETO predominantly contained immature myeloid precursors (EGFP + /cKit + /Mac-1 /Gr-1 cells; Fig. 3C ). Wright-Giemsa staining of the peripheral blood cells and bone marrow cells of mice from the AML1/ETO + KRAS group and AML1/ETO + NRAS by progressive anemia, leukocytosis, abnormal nuclei and cytoplasmic vacuoles, in the peripheral blood and bone marrow (Fig. 3A and B) . Histologic analyses revealed that in mice transplanted with AML1/ETO + KRAS or AML1/ETO + NRAS co-transduced cells, architecture of spleen and thymus in mice (Fig. 3D) .
We then examined the mRNA and protein expression of KRAS/K-ras, NRAS/N-ras and AML1/ETO in the bone marrow cells of the transplanted mice. The levels of KRAS mRNA increased in the bone marrow cells of the K-ras group and AML1/ETO + K-ras group (Fig.  4A) . K-ras protein expression was only upregulated in the bone marrow cells of the K-ras group and AML1/ETO + K-ras group (Fig. 4B) . A similar trend in the expression of N-ras Fig. 4A and B) . Overall Ras + K-ras and AML1/ETO + N-ras group (Fig. 4B) .
Discussion
Vectors based on lentiviruses show great promise as gene transfer vehicles due to their ability to transduce non-dividing cells [27] . Therefore, we constructed three lentiviral expression vectors (pCDH-K-ras G12D , pCDH-N-ras G12D and pCDH-AML1/ETO), which produced a high viral titer after infection of 293T cells (> 10 8 TU/mL). Accurate measurements
The ability of lentiviral vectors to infect 293T cells in vitro is not always indicative of the rates of infection for other types of cells. However, when mouse bone marrow cells were transduced with the pCDH-K-ras G12D vector or pCDH-N-ras G12D vector, the frequency of the EGFP + populations was > 90%. This demonstrates that co-infection of bone marrow cells with pCDH-K-ras G12D or pCDH-N-ras G12D and pCDH-AML1/ETO was reliable, sensitive, and reproducible.
Acute myeloid leukemia (AML) is a malignant disorder of the progenitor cells involved in genetic aberrations have been reported to be implicated in this disease [25] . It is thought that the emergence of AML requires cooperation between defects in myeloid differentiation and the presence of pro-proliferative mutations, typically involving the Ras signaling pathways [29] . N-ras (G12D) can cooperate with both AML1/ETO and MLL/ENL to accelerate the onset N-ras(G12D) was not oncogenic on its own; however, N-ras (G12D) cooperated with AML1/ ETO to accelerate disease progression compared with AML1/ETO alone (median survival 79 d vs. 150 d, P < 0.0001; Fig. 2 A) . The mammalian Ras subfamily proteins (H-Ras, N-Ras roles in numerous cellular processes. Furthermore, mutations in all three Ras isoforms may occur within the same tumor in some thyroid adenomas and carcinomas, suggesting that each isoform may contribute to different aspects of tumor growth [30] . Several animal models have also been generated to study the role of the K-ras mutation in tumorigenesis [1, [15] [16] [17] . For example, an animal model expressing the oncogenic K-ras LA allele was initially constructed via homologous recombination. However, K-ras LA mice develop a variety of tumor types including lung neoplasia [15] . Here we report that K-ras (G12D) cooperates with the AML1/ETO translocation to induce AML in mice (median survival, AML1/ETO + KRAS vs. KRAS, 115 vs. 150 d, P < 0.0001; AML1/ETO + KRAS vs. AML1/ETO, 115 vs. 150 d, P < 0.0001; Fig. 2A ). Wright-Giemsa-stained bone marrow cytocentrifugation revealed predominantly immature blasts in AML1/ETO + N-ras leukemia, while AML1/ETO + K-ras leukemia was also characterized by immature myelomonocytic cells at various levels of differentiation ( Fig. 3A and B) . Additionally, bone marrow immunphenotyping of AML1/ + /c-Kit + /Mac-1 /Gr-1 immature blasts. In summary, mosaic mouse models based on cooperation of K-ras with result is in support of the idea that K-ras mutations also play an important role in the pathogenesis of AML [31] .
Activating mutations in the ras genes, such as the N-ras mutation, are viewed as an additional hit in AML1/ETO-rearranged leukemia [25, 32, 33] . We observed similar results in this mouse model. Mice in the AML1/ETO + N-ras (G12D) group had the lowest median overall survival rate (79 d), similar to previous reports [25] . However, our evidence suggests [25, 34, 35] . Mice harboring leukemia coexpressing AML1/ETO together with N-ras (G12D) or K-ras (G12D) displayed progressive anemia and leukocytosis. Upon reaching a terminal disease stage, EGFP-positive cells dominated the spleen, lymph nodes, peripheral blood and central CNS of mice in the AML1/ETO+K-ras group. In conclusion, we generated a mouse model of leukemia which G12D cooperated with AML1/ETO to accelerate the onset of leukemia and reduce overall survival. These data demonstrate that mouse leukemias coexpressing AML1/ETO together with oncogenic K-ras can provide accurate yet distinct models of human AML which represent the typical clinical symptoms of different subtypes of human AML. These mouse models will be useful for studying the mechanisms by which K-ras mutations contribute to the development of myeloid leukemia, should prove useful for investigating the signaling pathways that promote self-renewal in AML, and may provide valuable tools for assessing the translational and post-transcriptional regulatory mechanisms that activate these pathways. In future research, we will investigate whether mice harboring leukemia coexpressing AML1/ETO together with N-ras (G12D) or K-ras (G12D) displaying progressive anemia and leukocytosis are regulated by the same mechanism. 
